PTHS Stock: Pelthos Therapeutics Inc. Stock Price, Analysis & Insights
Get live PTHS stock price $26.30, comprehensive Pelthos Therapeutics Inc. stock analysis, charts, news, and expert forecast. Real-time PTHS stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifi...
Company Information
- CEO
- Scott Plesha
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
Contact Information
- Website
- https://pelthos.com
- Address
- 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 3.20)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Pelthos Therapeutics Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Pelthos Therapeutics Inc.
- ⚠Investors should consider how Pelthos Therapeutics Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
17.06M
P/E Ratio (TTM)
-1.15
Beta
3.20
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare PTHS with peer companies:
- Price
- $0.15
- Market cap
- 2.33M
- Price
- $4.84
- Market cap
- 27.13M
- Price
- $0.41
- Market cap
- 2.15M
- Price
- $0.71
- Market cap
- 17.21M
- Price
- $0.43
- Market cap
- 9.23M
- Price
- $0.67
- Market cap
- 13.70M
- Price
- $7.12
- Market cap
- 88.17M
- Price
- $3.81
- Market cap
- 34.70M
- Price
- $1.84
- Market cap
- 4.04M
- Price
- $5.40
- Market cap
- 17.32M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.